Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc. (T:BHC)

Business Focus: Pharmaceuticals (NEC)

This company is also listed in the United States as BHC on the NYSE. Click here to get the live US quote and see if there are any SEC insider filings..
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Company Contact
Address: 2150 Saint-Elzear Blvd W
LAVAL QC H7L 4A8
Tel: 1-949-4616002
Website: https://www.bauschhealth.com
IR: See website
Key People
Joseph C. Papa
Chairman of the Board, Chief Executive Officer
Sam Eldessouky Will
Chief Financial Officer, Executive Vice President
Thomas J. Appio
President and Co-Head Bausch + Lomb/International
Joseph F. Gordon
President and Co-Head Bausch + Lomb/International
Robert A. Spurr
President - Salix
Christina M. Ackermann
Executive Vice President, General Counsel and Head of Commercial Operations
Paul S. Herendeen
Executive Vice President
   
Business Overview
Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.
Financial Overview
For the nine months ended 30 September 2021, BauschHealth Companies Inc revenues increased 7% to $6.24B. Netloss increased from $407M to $1.02B. Revenues reflect Salixsegment increase of 10% to $1.52B, Ortho Dermatologicssegment increase of 6% to $418M, China (Country) segmentincrease of 51% to $349M, United States and Puerto Ricosegment increase of 3% to $3.63B, United Kingdom segmentincrease from $21M to $83M.
Employees: 21,600 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $41,144M as of Sep 30, 2021
Annual revenue (TTM): $10,574M as of Sep 30, 2021
EBITDA (TTM): $3,966M as of Sep 30, 2021
Net annual income (TTM): -$1,464M as of Sep 30, 2021
Free cash flow (TTM): $1,892M as of Sep 30, 2021
Net Debt Last Fiscal Year: $27,111M as of Sep 30, 2021
Shares outstanding: 359,330,757 as of Oct 28, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization